Trial Profile
Phase 1, Open-Label, Randomized Study of the Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Elasomeran (Primary) ; MRNA 1273 351 (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions
- 26 Sep 2022 Status changed from active, no longer recruiting to completed.
- 17 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 01 Apr 2021 Status changed from not yet recruiting to recruiting.